Insider Selling: OS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $112,692.80 in Stock

OS Therapies Inc (NYSE:OSTX) major shareholder Shalom Auerbach sold 16,720 shares of OS Therapies stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total transaction of $112,692.80. Following the completion of the sale, the insider now owns 2,531,211 shares in the company, valued at $17,060,362.14. This trade represents a 0.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

OS Therapies Stock Performance

Shares of OSTX opened at $2.95 on Monday. The stock’s fifty day moving average price is $3.32. OS Therapies Inc has a 1-year low of $1.58 and a 1-year high of $7.00.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. D. Boral Capital reiterated a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a research note on Wednesday, January 15th. Maxim Group upped their target price on OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC purchased a new position in shares of OS Therapies Inc (NYSE:OSTX) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.